Oncogenic EGFR rewires STING-TBK1 immune machinery to license DNA damage tolerance
Qin Shen, Mei Chen, Yidan Chen…·Pinglong Xu
This study reveals that oncogenic EGFR mutations exploit the STING-TBK1 immune pathway to enhance DNA damage repair and therapeutic resistance in NSCLC.